title: Comparative decorporation efficacy of 3,4,3-LIHOPO, 4,4,4-LIHOPO and DTPA after contamination of rats with soluble forms of 238Pu and 233U.
abstract: The aim of this study was to compare the efficacies of DTPA, 3,4,3-LIHOPO and a newly synthesised molecule, 4,4,4-LIHOPO, in removing 233U and 238Pu after internal contamination by soluble forms of those nuclides. For this purpose, intravenous injections of DTPA (30 micromol kg(-1)) or 3,4,3-LIHOPO or 4,4,4-LIHOPO at dosages of 0.3 or 30 micromol kg(-1) were performed 1, 6 and 24 h after contamination of rats by intravenously injected 238Pu citrate and 1 h after intravenous injection of 233U nitrate. Actinide content in the main retention organs and cumulated excretion were measured 48 h after contamination. These experiments show similar decorporation efficacies of 4,4,4-LIHOPO and 3,4,3-LIHOPO for Pu, which are much higher than that of DTPA. At a dosage of 0.3 micromol kg(-1), the two LIHOPO analogues were as efficient as DTPA at a dosage of 30 micromol kg(-1). After U contamination, a 20% decorporation efficacy was obtained for either 3,4,3-LIHOPO or 4,4,4-LIHOPO at a dosage of 30 micromol kg(-1).
authors.affiliation: Laboratoire de Radiotoxicologie, CEA/DSV/DRR, BP 12, 91680 Bruyères le Châtel, France. beatrice.le-gall@cea.fr
authors.forename: B
authors.initials: B
authors.lastname: Ramounet-Le Gall
authors.forename: G
authors.initials: G
authors.lastname: Grillon
authors.forename: G
authors.initials: G
authors.lastname: Rateau
authors.forename: R
authors.initials: R
authors.lastname: Burgada
authors.forename: T
authors.initials: T
authors.lastname: Bailly
authors.forename: P
authors.initials: P
authors.lastname: Fritsch
mesh_terms: D000818:Animals; D001372:Aza Compounds / Q000008:administration & dosage*; D001822:Body Burden; D002614:Chelating Agents / Q000008:administration & dosage; D015913:Chelation Therapy / Q000379:methods*; D003666:Decontamination / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D005269:Femur / Q000187:drug effects / Q000378:metabolism; D007275:Injections, Intravenous; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D004369:Pentetic Acid / Q000008:administration & dosage*; D011005:Plutonium / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity; D011728:Pyridones / Q000008:administration & dosage*; D011832:Radiation Injuries / Q000209:etiology / Q000517:prevention & control*; D051381:Rats; D017207:Rats, Sprague-Dawley; D016896:Treatment Outcome; D014501:Uranium / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity; D014915:Whole-Body Counting
chemical_list: D001372:Aza Compounds; D002614:Chelating Agents; D011728:Pyridones; C076998:N,N',N'',N'''-tetra(1,2-dihydro-1-hydroxy-2-oxopyridine-6-carbonyl)-1,5,10,14-tetraazatetradecane; D014501:Uranium; D011005:Plutonium; D004369:Pentetic Acid